Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Predictive Value of the Pre-Operative CT Scan for Splenectomy in Patients with Primary, and Post Essential Thrombocythemia/Post Polycythemia Vera Myelofibrosis.

Ruben A. Mesa, MD, Brian Bartholmai, MD, Chin Y. Li, MD, Susan Schwager, Animesh Pardanani, MD, PHD, Kebede Hussein, MD, Ayalew Tefferi, MD

Blood (2007) 110 (11): 4632.

https://doi.org/10.1182/blood.V110.11.4632.4632

Published: 2007

Journal Articles

Risk Stratification for Survival and Leukemic Transformation in Essential Thrombocythemia: A Single Institutional Study of 605 Patients.

Naseema Gangat, MBBS, Alexandra Wolanskyj, MD, Rebecca F. McClure, MD, Chin Y. Li, MD, Susan M. Schwager, Wenting Wu, PhD, Ayalew Tefferi, MD

Blood (2006) 108 (11): 3599.

https://doi.org/10.1182/blood.V108.11.3599.3599

Published: 2006

Journal Articles

Monocytosis Is an Independent Risk Factor for Survival in Agnogenic Myeloid Metaplasia.

Michelle A. Elliott, MD, David Dingli, MD, PhD, Susan M. Schwager, Chin Y. Li, MD, Ayalew Tefferi, MD

Blood (2006) 108 (11): 3629.

https://doi.org/10.1182/blood.V108.11.3629.3629

Published: 2006

Journal Articles

Phase II Study of the Combination of Low-Dose Thalidomide, Prednisone, and Etanercept (PET Regimen) in the Treatment of Anemia, Splenomegaly, and Constitutional Symptoms Associated with Myelofibrosis with Myeloid Metaplasia (MMM).

Ruben A. Mesa, MD, David P. Stensma, MD, Chin Y. Li, MD, Antje Hoering, PhD, Jacob B. Allred, MS, Heather L. Powell, MS, Ayalew Tefferi, MD

Blood (2005) 106 (11): 2576.

https://doi.org/10.1182/blood.V106.11.2576.2576

Published: 2005

Journal Articles

Phase II Study of the Combination of Low-Dose Thalidomide, Prednisone, and Etanercept (“PET regimen”) in the Treatment of Anemia, Splenomegaly, and Constitutional Symptoms Associated with Myelofibrosis with Myeloid Metaplasia (MMM).

Ruben A. Mesa, MD, David P. Steensma, MD, Chin Y. Li, MD, Antje Hoering, PhD, Heather Powell, Ayalew Tefferi, MD

Blood (2004) 104 (11): 1520.

https://doi.org/10.1182/blood.V104.11.1520.1520

Published: 2004

NARROW

Predictive Value of the Pre-Operative CT Scan for Splenectomy in Patients with Primary, and Post Essential Thrombocythemia/Post Polycythemia Vera Myelofibrosis.

Risk Stratification for Survival and Leukemic Transformation in Essential Thrombocythemia: A Single Institutional Study of 605 Patients.

Monocytosis Is an Independent Risk Factor for Survival in Agnogenic Myeloid Metaplasia.

Phase II Study of the Combination of Low-Dose Thalidomide, Prednisone, and Etanercept (PET Regimen) in the Treatment of Anemia, Splenomegaly, and Constitutional Symptoms Associated with Myelofibrosis with Myeloid Metaplasia (MMM).

Phase II Study of the Combination of Low-Dose Thalidomide, Prednisone, and Etanercept (“PET regimen”) in the Treatment of Anemia, Splenomegaly, and Constitutional Symptoms Associated with Myelofibrosis with Myeloid Metaplasia (MMM).

Email alerts

ASH Publications

American Society of Hematology

Predictive Value of the Pre-Operative CT Scan for Splenectomy in Patients with Primary, and Post Essential Thrombocythemia/Post Polycythemia Vera Myelofibrosis.

Risk Stratification for Survival and Leukemic Transformation in Essential Thrombocythemia: A Single Institutional Study of 605 Patients.

Monocytosis Is an Independent Risk Factor for Survival in Agnogenic Myeloid Metaplasia.

Phase II Study of the Combination of Low-Dose Thalidomide, Prednisone, and Etanercept (PET Regimen) in the Treatment of Anemia, Splenomegaly, and Constitutional Symptoms Associated with Myelofibrosis with Myeloid Metaplasia (MMM).

Phase II Study of the Combination of Low-Dose Thalidomide, Prednisone, and Etanercept (“PET regimen”) in the Treatment of Anemia, Splenomegaly, and Constitutional Symptoms Associated with Myelofibrosis with Myeloid Metaplasia (MMM).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only